Search clinical trials for: Eslicarbazepine acetate 1600 mg

Total 2159 results

Bial - Portela C S.A.

Terminated

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

BIPOLAR I DISORDER
Sunovion

Completed

Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic

Epilepsy

United States, Bulgaria, Czech Republic, Serbia, Ukraine
Bial - Portela C S.A.
Sunovion

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Partial Epilepsy

United States, Argentina, Germany, France, Belgium, Canada, Italy, Poland, Greece, Brazil, Cyprus
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia

Fibromyalgia
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy
Bial - Portela C S.A.

Completed

A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

Epilepsy

United States
Bial - Portela C S.A.

Completed

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

Epilepsy

Germany
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

Bipolar I Disorder
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

Influenza

China
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine

Migraine
Bial - Portela C S.A.

Completed

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

Partial Epilepsy

Portugal
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia

Post Herpetic Neuralgia

Germany
Bial - Portela C S.A.

Completed

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Epilepsy

Spain, Bulgaria, Austria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania
Centre Hospitalier Saint Joseph Saint Luc de Lyon

Unknown

ZEBinix® Retention Rate in Epilepsy in Elderly Patients (ZEBRE)

Epilepsy | Aging | Epilepsy; Seizure | Aging Disorder

France
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures

Refractory Partial Epilepsy

Portugal
UCB Pharma

Completed

Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Japan
Bial - Portela C S.A.

Completed

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

Epilepsy

Romania
Bial - Portela C S.A.

Completed

An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Epilepsy

South Africa
Bial - Portela C S.A.

Completed

A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093

Epilepsy
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093

Epilepsy

Portugal
Eisai Inc.

Completed

A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)

Partial Onset Seizures

France, United Kingdom, Germany, Denmark, Czech Republic, Norway, Sweden, Ireland
Gmax Biopharm LLC.

Recruiting

A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, China
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

Epilepsy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers

Asthma; Allergic Rhinitis

China
Bial - Portela C S.A.

Completed

Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate

Epilepsy
Exeltis Turkey
Monitor CRO

Active, not recruiting

Bioavailability Study of EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule

Bioavailability

Turkey
Bial - Portela C S.A.

Completed

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

Epilepsy

United Kingdom
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

Partial Epilepsy in Children and Adolescents

United Kingdom, Spain, Serbia, Italy, Austria, Bosnia and Herzegovina, Croatia, Czechia, France, Germany, Hungary, Malaysia, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Taiwan, Ukr...
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures

Partial Epilepsy

Netherlands, Poland, Italy, Russian Federation, Ukraine
Ministry of Health, Turkey
Istanbul University; Ankara Training and Research Hospital; Prof. Dr. Cemil Tascıoglu... and other collaborators

Active, not recruiting

Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

COVID-19 | Sars-CoV2

Turkey
Bial - Portela C S.A.

Completed

Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate

Epilepsy
Bial - Portela C S.A.

Completed

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

Epilepsy
Bial - Portela C S.A.

Completed

A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093

Epilepsy

United Kingdom
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Bial - Portela C S.A.

Completed

Bioequivalence of Two Different Sources of Eslicarbazepine Acetate

Epilepsy
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain

Painful Diabetic Neuropathy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy

Partial Epilepsy

Portugal
Abbott
PPD

Completed

Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group (EXPO)

Non Alcoholic Fatty Liver Disease

France, Germany, Poland, Russian Federation
Bial - Portela C S.A.

Completed

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

Epilepsy

Portugal
Repros Therapeutics Inc.

Completed

Extension of Study ZPV-200

Uterine Fibroids

United States
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy

Portugal
Janssen Research & Development, LLC

Completed

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

Healthy

United States
Ilkos Therapeutic Inc.

Completed

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

Venous Leg Ulcer

Spain, Hungary, Canada, United States, Brazil, Argentina, Austria, Czechia, Italy, Poland, Slovakia
Bial - Portela C S.A.

Completed

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

Epilepsy
Bial - Portela C S.A.

Completed

Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours

Epilepsy

Romania, Slovakia
Bial - Portela C S.A.

Completed

Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive

Partial Epilepsy

Portugal
GlaxoSmithKline

Completed

A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

Diabetes Mellitus, Type 2

United States, Taiwan, Argentina, Canada, Philippines, Korea, Republic of, Mexico, Brazil, Pakistan
Sunovion

Completed

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

Epilepsy With Partial On-set Seizures

United States, Canada

3

Subscribe